Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Conditions
Interventions
Oregovomab
Paclitaxel
+2 more
Locations
14
India
Omega Hospitals
Visakhapatnam, Andhra Pradesh, India
King George Hospital
Visakhapatnam, Andhra Pradesh, India
Himalaya Cancer Hospital and Research Institute
Vadodara, Gujarat, India
Kailash Cancer Hospital and Research Centre
Vadodara, Gujarat, India
KLES Dr. Prabhakar Kore Hospital and Medical Research Centre
Belagavi, Karnataka, India
Amrita Institute of Medical Sciences
Kochi, Kerala, India
Start Date
February 7, 2023
Primary Completion Date
October 15, 2026
Completion Date
September 15, 2027
Last Updated
April 1, 2026
NCT06257264
NCT06964009
NCT05005403
NCT06710548
NCT06547840
NCT05735080
Lead Sponsor
CanariaBio Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions